CCDC 115 Congenital Disorder of Glycosylation

CCDC115-CDG (also called congenital disorder of glycosylation type IIo) is a very rare inherited disease where the body has trouble doing a key “sugar-finishing” job called glycosylation. Glycosylation helps many proteins work correctly, so when it is disturbed, many organs can be affected, especially the liver, muscles (low tone), and brain/development. It usually starts in infancy or childhood and can look like other liver or metabolic diseases, which can delay diagnosis. PubMed+3PMC+3Genetic Diseases Info Center+3

This condition happens because of changes (variants) in the CCDC115 gene (also known as VMA22 in some databases). The CCDC115 protein helps keep the Golgi system working well. The Golgi is like a “shipping and packaging center” inside cells. When the Golgi is not working well, the body makes proteins with abnormal sugar patterns, and this can disturb liver function, blood clotting factors, cholesterol balance, and other systems. NCBI+3PMC+3PubMed+3

Many reported patients have hepatosplenomegaly (big liver/spleen), high liver enzymes, and sometimes progressive liver disease. Some also have developmental delay, hypotonia (low muscle tone), and seizures. Blood tests may show clotting problems, high cholesterol, and low ceruloplasmin, which can confuse doctors because it may look like other liver conditions. PMC+3Genetic Diseases Info Center+3orpha.net+3

CCDC115-CDG is a very rare genetic (inherited) disorder where the body has trouble adding and editing sugar chains (glycans) on many proteins. These sugar chains work like “labels” that help proteins fold correctly, move to the right place, and do their jobs. When glycosylation is abnormal, many organs can be affected, especially the liver and the nervous system. NCBI+2SpringerLink+2

In CCDC115-CDG, the problem happens mainly in the Golgi apparatus, which is a cell “packing and finishing” area that modifies proteins before they are sent out. Studies describe CCDC115-CDG as a disorder of Golgi homeostasis, meaning the Golgi’s normal working balance (including trafficking and proper internal conditions) is disturbed, leading to abnormal glycosylation patterns. PubMed+2PubMed+2

This condition is typically autosomal recessive, meaning a child is affected when they inherit two disease-causing variants, one from each parent (parents are usually healthy carriers). Many reported patients have early onset disease with hepatosplenomegaly (large liver and spleen), progressive liver disease, low muscle tone, and developmental delay, plus characteristic lab findings like abnormal transferrin glycosylation and liver-related blood test changes. NCBI+1

Another names

CCDC115-CDG is also called CDG IIo or CDG2O, which are older “type” names based on lab patterns, and it may be described as Congenital disorder of glycosylation, type IIo. It is also listed as Carbohydrate-deficient glycoprotein syndrome type IIo in some medical systems. NCBI+1

Some databases also connect the condition to the name VMA22 (related naming used for the gene/region in some records), but modern naming usually uses CCDC115-CDG. NCBI+1

Types

• Biochemical “Type II” CDG pattern (Golgi processing defect): type II patterns are linked to problems after the early steps of glycosylation, often in the Golgi. SpringerLink+1

• Predominant/isolated liver involvement type: some CDG (including CCDC115-CDG) can present mainly with liver disease compared with other CDG forms. Frontiers+1

• Liver + neurodevelopmental involvement type: some patients have both severe liver disease and neurological/developmental problems. PubMed+1

• Variable severity type (milder vs severe): published cases show a spectrum from later liver-predominant disease to earlier severe disease with more systems involved. PubMed+

Causes

1. Biallelic (two-copy) disease variants in CCDC115: this is the root cause in most confirmed cases, fitting an autosomal recessive disorder. NCBI+1

2. Carrier parents passing one altered copy each: this family pattern explains why parents can look healthy while a child is affected. NCBI+1

3. Homozygous variants (same variant from both parents): more likely when parents are related (consanguinity), increasing the chance both carry the same variant. NCBI+1

4. Compound heterozygous variants (two different variants): some affected people have two different harmful variants, one on each copy of the gene. NCBI+1

5. Loss-of-function variant effects: variants that reduce or stop protein function can disrupt cellular pathways strongly and may relate to more severe disease. SpringerLink+1

6. Missense variant effects (protein works poorly): some variants change one amino acid and can still cause disease by weakening the protein’s normal role. SpringerLink+1

7. Splice-site variants (wrong gene “cut and paste”): changes that disturb splicing can create an abnormal protein or too little protein. SpringerLink+1

8. Frameshift/nonsense variants (early stop signals): these often lead to a shortened, non-working protein, which can worsen cell dysfunction. SpringerLink+1

9. Golgi vesicle trafficking disturbance: CCDC115-CDG is grouped with disorders that disturb Golgi trafficking, which is important for correct glycosylation. PubMed+1

10. Golgi internal environment imbalance (including pH/acidification issues): some Golgi-homeostasis CDG (including CCDC115-CDG) are linked to abnormal lumen conditions that affect enzyme activity. PubMed+1

11. Combined N- and O-glycosylation disruption: lab descriptions note patterns suggesting defects affecting more than one glycosylation “branch,” consistent with a Golgi problem. NCBI+1

12. Mis-processing of liver-made glycoproteins (coagulation proteins, transport proteins): liver disease and clotting factor problems can happen when glycosylation is abnormal. NCBI+1

13. Low ceruloplasmin due to abnormal processing/handling: low ceruloplasmin is reported in this condition and can point to disturbed protein production/processing. NCBI+1

14. Copper metabolism disturbance and copper accumulation in liver: several reports highlight copper-related abnormalities that can resemble Wilson disease. NCBI+2PubMed+2

15. Chronic liver injury leading to fibrosis/cirrhosis: liver scarring can develop over time in reported cases, especially when disease begins early. PubMed+1

16. Secondary nutritional stress (poor feeding/failure to thrive): many CDG conditions can cause feeding difficulties and poor growth, which then worsens overall health. SpringerLink+1

17. Recurrent infections worsening illness burden (when immune issues are present): immune involvement is recognized across CDG, and infections can trigger decline in fragile infants. revistas.rcaap.pt+1

18. Coagulation instability (easy bleeding/bruising risk) from liver dysfunction: clotting factor deficiencies are commonly listed in CDG with liver involvement. NCBI+1

19. Metabolic “stress events” (illness, dehydration) aggravating liver dysfunction: in multisystem genetic metabolic disorders, intercurrent illnesses can unmask or worsen organ dysfunction. SpringerLink+1

20. Diagnostic delay due to “look-alike” diseases (mitochondrial, Niemann-Pick C, Wilson disease): some published cases emphasize that patients were first suspected to have other liver/metabolic diseases, delaying targeted care. PubMed+1

Symptoms

1. Hepatomegaly (large liver): the liver becomes bigger than normal, often noticed by a doctor during an exam or ultrasound. NCBI+1

2. Splenomegaly (large spleen): the spleen can also enlarge, sometimes causing a full belly feeling or low blood cell counts. NCBI+1

3. Hepatosplenomegaly: this means both the liver and spleen are enlarged, which is commonly reported in CCDC115-CDG. NCBI+1

4. Prolonged neonatal jaundice: yellow skin/eyes that lasts longer than expected in newborns can be an early liver sign. NCBI+1

5. Cholestasis (poor bile flow): bile does not move normally from the liver, which can cause jaundice, pale stool, and itching later on. NCBI+1

6. Progressive liver failure: the liver gradually loses function, affecting detox, protein production, and digestion. NCBI+1

7. Liver fibrosis/cirrhosis: long-term liver damage can lead to scarring and “hard” liver tissue, sometimes early in life. NCBI+1

8. Low muscle tone (hypotonia): babies may feel “floppy,” have weak head control, or tire easily. NCBI+1

9. Global developmental delay: a child may be slower to sit, crawl, walk, speak, or learn compared with typical milestones. NCBI+1

10. Delayed psychomotor development: this means slower progress in movement plus thinking/learning skills, often described in CDG2O. NCBI+1

11. Seizures: some patients have episodes caused by abnormal electrical activity in the brain; severity can vary. NCBI+1

12. Muscle wasting/atrophy: muscle mass can decrease over time, making weakness more noticeable. NCBI+1

13. Ptosis (droopy eyelids): one or both eyelids can droop and may affect vision if severe. NCBI+1

14. Signs linked to abnormal clotting (easy bruising/bleeding): liver-made clotting proteins can be low, so bleeding problems may happen. NCBI+1

15. Recurrent infections or immune weakness (in some CDG patients): some CDG types have immunodeficiency features; when present, children may get frequent or severe infections that need medical care. Frontiers+1

Diagnostic tests

Physical exam (doctor’s exam)

1. Abdominal exam for liver/spleen size: the clinician gently feels the belly to check if the liver or spleen is enlarged. NCBI+1

2. Jaundice check (skin/eyes): the clinician looks for yellow discoloration that suggests bilirubin and liver/bile problems. NCBI+1

3. Neurologic exam (tone, reflexes, alertness): hypotonia and developmental concerns can be found with a standard neuro exam. NCBI+1

4. Growth and nutrition assessment: height/weight/head size and feeding history help detect failure to thrive seen in many CDG conditions. SpringerLink+1

Manual tests (hands-on bedside functional assessments)

5. Developmental screening tools (age-appropriate): structured checks of motor, language, and social milestones help document global delay. NCBI+1

6. Feeding and swallowing bedside assessment: clinicians and speech/feeding specialists look for weak sucking, choking, or fatigue with feeds, common in complex metabolic disorders. SpringerLink+1

7. Manual muscle strength assessment: a clinician estimates strength (as age-appropriate) to track weakness and muscle atrophy over time. NCBI+1

8. Range-of-motion and tone assessment: hands-on testing helps describe hypotonia and detect contractures that can develop with long-term weakness. SpringerLink+1

Lab and pathological tests

9. Serum transferrin isoelectric focusing (IEF): a classic first-line screen for many CDG; type I vs type II patterns help guide next steps. SpringerLink+2cdghub.com+2

10. Mass spectrometry or HPLC-based transferrin testing: modern labs may use these as sensitive ways to detect transferrin glycosylation abnormalities. gimjournal.org+1

11. Expanded glycomics (serum N-glycan profiling): specialized testing can show glycan pattern changes and can help confirm/clarify CDG types. SpringerLink+1

12. Liver enzymes (ALT/AST) and cholestasis markers: blood tests can show liver injury and bile flow problems (common in reported CCDC115-CDG). NCBI+1

13. Coagulation profile (PT/INR, factor levels): checks for clotting factor deficiency related to liver dysfunction and abnormal glycoprotein production. NCBI+1

14. Serum ceruloplasmin and copper studies: low ceruloplasmin and copper abnormalities can appear and may mimic Wilson disease. NCBI+2PubMed+2

15. Lipid panel (cholesterol): mild to marked hypercholesterolemia is reported in CDG2O/CCDC115-CDG. NCBI+1

16. Genetic testing (gene panel / exome / genome sequencing): DNA testing is the confirmatory step, and modern practice uses WES/WGS often for CDG diagnosis. SpringerLink+1

17. Liver biopsy (selected cases): when needed, tissue can show fibrosis/cirrhosis or other patterns and help rule out look-alike diseases (used carefully). PubMed+1

Electrodiagnostic tests

18. EEG (brain wave test): if seizures or episodes are suspected, EEG helps confirm abnormal brain electrical activity. NCBI+1

19. EMG and nerve conduction studies (when indicated): these can help evaluate weakness, neuropathy, or muscle disease if the clinical picture suggests it. SpringerLink+1

Imaging tests

20. Abdominal ultrasound (liver/spleen): imaging measures organ size and looks for signs of chronic liver disease or portal hypertension. NCBI+1

(Extra commonly used imaging in CDG care, depending on symptoms, can include brain MRI for developmental/neurologic features, but the need is decided by a specialist.) SpringerLink+1

Treatment

Right now, there is no single “cure medicine” approved specifically for CCDC115-CDG. Treatment is usually supportive and symptom-based, meaning doctors treat the liver problems, nutrition issues, seizures, hormone issues, and infections as needed. Expert reviews on CDG care explain that most CDGs still depend on multidisciplinary care while research continues. PMC+2PMC+2

Non-Pharmacological Treatments (Therapies + Other Care)

1) Multidisciplinary care team. A coordinated team (metabolic/genetics, liver, neurology, dietitian, PT/OT, etc.) reduces missed problems and improves long-term support. Purpose: organize care. Mechanism: regular screening + fast response to new issues. NCBI+2PMC+2

2) Genetic counseling for family. Families learn inheritance risks and testing choices. Purpose: informed planning. Mechanism: explains autosomal-recessive inheritance and options for relatives. orpha.net+2Genetic Diseases Info Center+2

3) Regular liver monitoring. Track liver enzymes, bilirubin, clotting, ultrasound as advised. Purpose: catch worsening early. Mechanism: trends show progression before severe symptoms. Genetic Diseases Info Center+2PubMed+2

4) Nutrition assessment and growth tracking. Many CDG patients struggle with growth/feeding. Purpose: prevent malnutrition. Mechanism: calories/protein adjusted to needs; monitor weight/height. PMC+2PMC+2

5) Feeding therapy (swallow + safe eating). Helps chewing, swallowing, and texture tolerance. Purpose: reduce choking/aspiration risk. Mechanism: training muscles and safe feeding techniques. PMC+2PMC+2

6) Physical therapy (PT). Improves strength, balance, posture, and mobility. Purpose: reduce hypotonia impact. Mechanism: repeated guided movement builds motor skills. PMC+2PMC+2

7) Occupational therapy (OT). Builds daily-life skills (grip, dressing, writing). Purpose: independence. Mechanism: task practice + adaptive tools. PMC+2PMC+2

8) Speech and language therapy. Supports communication and (if needed) swallowing. Purpose: better speech/learning. Mechanism: structured language training and alternative communication tools. PMC+2PMC+2

9) Developmental/learning support plan. School supports (IEP/extra time) match the child’s needs. Purpose: better education access. Mechanism: targeted teaching reduces learning gaps. PMC+2PMC+2

10) Seizure action plan. Families learn what to do during seizures and when to call emergency help. Purpose: safety. Mechanism: fast response reduces complications and fear. Genetic Diseases Info Center+2PMC+2

11) Sleep routine and sleep problem screening. Poor sleep worsens learning and behavior. Purpose: improve daytime function. Mechanism: consistent timing and treating triggers improves sleep quality. PMC+2PMC+2

12) Vision screening. Early eye checks prevent missed vision problems that can slow development. Purpose: learning support. Mechanism: glasses/therapy help brain process vision better. PMC+2PMC+2

13) Hearing screening. Hearing issues can look like “speech delay.” Purpose: correct hidden barrier. Mechanism: hearing aids/therapy improve communication outcomes. PMC+2PMC+2

14) Safe infection-prevention habits. Hand hygiene, dental care, avoiding sick contacts when possible. Purpose: fewer infections. Mechanism: reduces germ exposure and inflammation stress. Frontiers+2PMC+2

15) Vaccination planning with doctors. Keep routine vaccines updated; special plans if immune issues exist. Purpose: prevent severe infections. Mechanism: trained immune memory lowers infection risk. Frontiers+2PMC+2

16) Liver-safe lifestyle. Avoid alcohol and unnecessary liver-toxic products; review all meds with doctors. Purpose: protect liver reserve. Mechanism: reduces extra liver workload. Wiley Online Library+2AASLD+2

17) Bleeding-risk safety steps. Use soft toothbrush, avoid risky sports if clotting is low. Purpose: reduce bleeding events. Mechanism: lowers trauma to gums/skin. Genetic Diseases Info Center+2NCBI+2

18) Mental health + caregiver support. Chronic rare diseases cause stress. Purpose: resilience. Mechanism: counseling and support groups improve coping and follow-through. PMC+2PMC+2

19) Emergency “medical summary” card. A short document listing diagnosis, risks, meds, and doctor contacts. Purpose: faster safe ER care. Mechanism: prevents delays and wrong assumptions. PMC+2PMC+2

20) Palliative care (supportive care) when needed. This is not “giving up.” It helps pain, feeding, sleep, and family goals. Purpose: quality of life. Mechanism: symptom control + planning reduces suffering. PMC+2PMC+2

Drug Treatments

Because CCDC115-CDG has no single curative drug, the medicines below are commonly used to treat complications (seizures, liver bile flow problems, endocrine issues, infections, nausea, reflux, nutrition, and blood/immune problems). PMC+2PMC+2

1) Levetiracetam (Keppra). Class: antiepileptic. Dosage/Time: individualized; often given 2 times daily. Purpose: seizure control. Mechanism: helps stabilize brain signaling. Side effects: sleepiness, dizziness, mood/behavior change. FDA Access Data

2) Valproic acid (Depakene/Depakote). Class: antiepileptic. Dosage/Time: individualized; often 2–3 times daily. Purpose: seizures. Mechanism: increases calming signaling in the brain. Side effects: nausea, tremor, liver toxicity risk, low platelets. FDA Access Data

3) Levothyroxine (Synthroid). Class: thyroid hormone replacement. Dosage/Time: usually once daily, often before breakfast. Purpose: treat hypothyroidism if present. Mechanism: replaces thyroid hormone for metabolism and growth. Side effects: fast heartbeat, anxiety if dose too high. FDA Access Data

4) Hydrocortisone (Cortef). Class: corticosteroid. Dosage/Time: individualized; often split doses. Purpose: adrenal replacement if adrenal insufficiency exists. Mechanism: replaces cortisol needed for stress response. Side effects: weight gain, high sugar, infection risk with high doses. FDA Access Data

5) Ursodiol (Actigall). Class: bile acid. Dosage/Time: individualized; often 2–3 times daily. Purpose: cholestasis/bile flow problems. Mechanism: makes bile less toxic and can improve bile flow. Side effects: diarrhea, stomach upset. FDA Access Data

6) Phytonadione (Vitamin K1; AquaMEPHYTON/Mephyton). Class: vitamin/coagulation support. Dosage/Time: clinician-directed (oral or injection). Purpose: help correct vitamin K deficiency and clotting problems. Mechanism: supports making clotting factors. Side effects: injection reactions; allergy is rare but possible. FDA Access Data+1

7) Lactulose (solution). Class: osmotic laxative; also used for portal-systemic encephalopathy. Dosage/Time: titrated to soft stools. Purpose: constipation and, in liver disease, reduce encephalopathy risk. Mechanism: changes colon acids and traps ammonia for removal. Side effects: gas, diarrhea, dehydration if too much. DailyMed+2DailyMed+2

8) Rifaximin (Xifaxan). Class: gut-targeted antibiotic. Dosage/Time: commonly twice daily (label depends on indication). Purpose: reduce hepatic encephalopathy recurrence in liver disease. Mechanism: lowers ammonia-producing gut bacteria. Side effects: nausea, swelling, rare severe diarrhea. FDA Access Data+2AASLD+2

9) Spironolactone (Aldactone). Class: potassium-sparing diuretic/aldosterone blocker. Dosage/Time: clinician-directed. Purpose: fluid overload/ascites in liver disease. Mechanism: helps body remove salt/water while holding potassium. Side effects: high potassium, breast tenderness/gynecomastia. FDA Access Data

10) Furosemide (Lasix). Class: loop diuretic. Dosage/Time: clinician-directed; often morning dosing. Purpose: edema/ascites. Mechanism: helps kidneys remove salt and water. Side effects: low potassium, dehydration, low blood pressure. FDA Access Data

11) Ceftriaxone (Rocephin). Class: cephalosporin antibiotic. Dosage/Time: clinician-directed (often IV/IM). Purpose: serious bacterial infections. Mechanism: damages bacterial cell wall building. Side effects: diarrhea, allergy, biliary sludge in some patients. FDA Access Data

12) Amoxicillin/clavulanate (Augmentin). Class: penicillin antibiotic + beta-lactamase inhibitor. Dosage/Time: often taken at start of a meal (label guidance). Purpose: common bacterial infections. Mechanism: kills bacteria and blocks resistance enzymes. Side effects: diarrhea, rash, yeast infection. FDA Access Data

13) Ondansetron (Zofran). Class: anti-nausea (5-HT3 blocker). Dosage/Time: as prescribed, often before triggers. Purpose: nausea/vomiting. Mechanism: blocks serotonin signals that trigger vomiting. Side effects: constipation, headache; QT rhythm risk in some. FDA Access Data

14) Omeprazole (Prilosec). Class: proton pump inhibitor (PPI). Dosage/Time: often before eating (label guidance). Purpose: reflux, stomach acid injury. Mechanism: lowers stomach acid production. Side effects: diarrhea, low magnesium with long use, infection risks. FDA Access Data+1

15) Pancrelipase (Creon). Class: pancreatic enzyme replacement. Dosage/Time: taken with meals/snacks when prescribed. Purpose: malabsorption if pancreatic insufficiency exists. Mechanism: replaces digestive enzymes (lipase, amylase, protease). Side effects: stomach pain, constipation/diarrhea; high doses can irritate gut. FDA Access Data

16) Filgrastim (Neupogen). Class: G-CSF growth factor. Dosage/Time: clinician-directed injections. Purpose: raise neutrophils if severe neutropenia occurs. Mechanism: signals bone marrow to make more neutrophils. Side effects: bone pain; rare spleen rupture risk. FDA Access Data

17) Pegfilgrastim (Neulasta). Class: long-acting G-CSF. Dosage/Time: usually single dose per cycle in approved uses; clinician decides for off-label needs. Purpose: prolonged neutrophil support in selected cases. Mechanism: same pathway as filgrastim but lasts longer. Side effects: bone pain; rare lung/vascular events. FDA Access Data+1

18) Levocarnitine (Carnitor). Class: metabolic/nutrition drug. Dosage/Time: clinician-directed oral or IV. Purpose: carnitine deficiency or certain metabolic stresses. Mechanism: helps move fats into mitochondria for energy use. Side effects: fishy odor, diarrhea, stomach upset. FDA Access Data+1

19) Calcitriol. Class: active vitamin D hormone. Dosage/Time: clinician-directed. Purpose: treat low calcium/low vitamin D hormone states when indicated. Mechanism: increases calcium absorption and bone mineral support. Side effects: high calcium, kidney stones if overdosed. FDA Access Data

20) M.V.I. Pediatric (multiple vitamins injection). Class: injectable vitamin combination. Dosage/Time: used in hospital nutrition plans when oral intake is not possible. Purpose: prevent vitamin deficiency in patients needing IV nutrition. Mechanism: supplies essential vitamins for metabolism and healing. Side effects: allergy is rare; too much of some vitamins can harm. FDA Access Data

Dietary Molecular Supplements

Supplements do not fix the gene problem, but they may help correct deficiencies and support general health when your clinician confirms a need. PMC+2PMC+2

1) Vitamin D (D3). Dosage: depends on blood level. Function: bone strength and immune balance. Mechanism: regulates calcium and immune signaling. Note: too much can raise calcium. orpha.net

2) Zinc. Dosage: depends on diet/labs. Function: immunity, wound healing, taste/appetite. Mechanism: supports enzyme and immune cell work. Note: excess can lower copper. PubMed

3) Folate (Folic acid). Dosage: clinician-guided. Function: red blood cells and growth. Mechanism: helps DNA building and cell division. Note: can mask B12 deficiency if used alone. Cell

4) Vitamin B12. Dosage: oral or injection based on cause. Function: nerves and blood cells. Mechanism: supports myelin and red cell formation. Note: check levels first. NCBI

5) Selenium. Dosage: small amounts; avoid high dosing. Function: antioxidant defense and thyroid support. Mechanism: part of selenoproteins that reduce oxidative stress. Note: too much can be toxic.

6) Omega-3 (fish oil/DHA/EPA). Dosage: varies. Function: brain and heart support; may help inflammation balance. Mechanism: changes cell membrane fats and signaling molecules. Note: can increase bleeding risk in high doses. PubMed

7) Magnesium. Dosage: depends on labs and kidney function. Function: muscle/nerve function and energy. Mechanism: cofactor for many enzymes. Note: too much can cause diarrhea. FDA Access Data

8) Riboflavin (Vitamin B2). Dosage: clinician-guided. Function: energy pathways. Mechanism: supports flavoproteins used in metabolism. Note: bright yellow urine is common and harmless. FDA Access Data

9) Thiamin (Vitamin B1). Dosage: depends on risk and intake. Function: nerve function and carbohydrate energy use. Mechanism: key enzyme helper in glucose metabolism. Note: deficiency can be serious. FDA Access Data

10) Coenzyme Q10. Dosage: varies widely. Function: mitochondrial energy support (general). Mechanism: electron transport chain support and antioxidant effects. Note: evidence differs by condition. PubMed+1

Immunity Booster / Regenerative / Stem Cell” Medical Options

Some CCDC115-CDG patients may have immune stress or severe organ disease; these options are case-by-case and must be supervised by specialists. Frontiers+2PMC+2

1) IVIG (immune globulin) replacement. Dosage: weight-based and individualized. Function: replaces missing antibodies. Mechanism: gives ready-made IgG to help fight infections. Risks: thrombosis, kidney problems, infusion reactions. U.S. Food and Drug Administration+1

2) SCIG (subcutaneous immune globulin). Dosage: smaller doses more often. Function: long-term antibody support at home for some patients. Mechanism: slow absorption under skin keeps steadier IgG levels. Risks: local swelling, headaches. U.S. Food and Drug Administration+1

3) Filgrastim (G-CSF). Dosage: clinician-directed. Function: boosts neutrophils in severe neutropenia. Mechanism: signals marrow to produce neutrophils faster. Risks: bone pain; rare spleen issues. FDA Access Data

4) Pegfilgrastim (long-acting G-CSF). Dosage: clinician-directed. Function: longer neutrophil support when appropriate. Mechanism: same G-CSF pathway with longer activity. Risks: bone pain; rare lung problems. FDA Access Data+1

5) Epoetin alfa (Epogen) for severe anemia in selected situations. Dosage: clinician-directed. Function: reduces transfusion need in approved uses. Mechanism: stimulates red blood cell production. Risks: blood clots, high blood pressure, stroke risk when misused. FDA Access Data+1

6) Stem cell transplant (HSCT) and other regenerative ideas. For CCDC115-CDG, stem-cell treatments are not standard and are usually considered only in special cases or research settings. Mechanism idea: replace defective blood/immune cells, not fix every organ. Risk: high and complex. PMC+1

Surgeries / Procedures

1) Gastrostomy tube (G-tube). Done when swallowing is unsafe or calories are not enough. It helps stable nutrition and medication delivery. PMC+2PMC+2

2) Fundoplication (anti-reflux surgery). Considered if severe reflux causes aspiration, poor growth, or feeding failure. It reduces back-flow from stomach to esophagus. PMC+2PMC+2

3) Central venous access (port/central line). Used when frequent IV treatments or long-term nutrition is needed. It reduces repeated needle sticks but raises infection risk. PMC+2PMC+2

4) Liver transplant. Considered if progressive liver failure becomes life-threatening. It replaces the failing organ but does not change the gene in other tissues. Genetic Diseases Info Center+2Wiley Online Library+2

5) Orthopedic surgery (contractures/scoliosis/hip issues). Done if mobility or pain becomes severe. It can improve function and comfort when therapy alone is not enough. PMC+2PMC+2

Prevention Tips

1) Early diagnosis + regular follow-up lowers missed complications. PubMed+2PMC+2

2) Keep vaccines up to date (with specialist advice if immune issues). Frontiers+2PMC+2

3) Hand hygiene and dental care to reduce infection sources. Frontiers+2PMC+2

4) Nutrition plan to prevent poor growth and vitamin/mineral deficits. PMC+2PMC+2

5) Avoid dehydration (diarrhea/fever can worsen weakness and liver stress). DailyMed+2FDA Access Data+2

6) Review all medicines for liver safety with your doctor/pharmacist. Wiley Online Library+2PMC+2

7) Bleeding-risk safety habits if clotting factors are low. NCBI+2Genetic Diseases Info Center+2

8) Seizure safety (sleep, triggers, helmet rules if needed). PMC+2Genetic Diseases Info Center+2

9) Regular vision/hearing checks to protect learning. PMC+2PMC+2

10) Family genetic counseling for future pregnancy planning. orpha.net+2Genetic Diseases Info Center+2

When to See a Doctor

See a doctor soon if there is poor weight gain, repeated vomiting/diarrhea, new jaundice (yellow eyes/skin), new bruising/bleeding, increasing belly size, frequent infections, or new developmental regression. Genetic Diseases Info Center+2orpha.net+2

Go to urgent/emergency care for seizures that don’t stop as expected, severe sleepiness/confusion (possible severe liver complication), vomiting blood/black stools, trouble breathing, severe dehydration, or signs of severe infection (high fever, extreme weakness). AASLD+2AASLD+2

What to Eat and What to Avoid

1) Eat enough calories and protein (doctor/dietitian guided) and avoid skipping meals if you struggle with growth. PMC+2PMC+2

2) Choose nutrient-dense foods (eggs, fish, legumes, dairy if tolerated) and avoid “empty calorie” junk most days. PMC+2PMC+2

3) Use safe fats (olive oil, nuts if safe) and avoid very high trans-fat foods (deep fried/processed) to support heart/liver health. PMC+2Wiley Online Library+2

4) Drink enough water and avoid dehydration (especially during diarrhea/fever). DailyMed+2PMC+2

5) If liver disease is severe, follow salt advice (sometimes low-salt) and avoid very salty snacks to reduce fluid buildup. Wiley Online Library+2PMC+2

6) Use fiber carefully (fruits/vegetables) and avoid sudden huge fiber jumps that worsen bloating/diarrhea. DailyMed+2PMC+2

7) Use supplements only if needed and avoid megadoses (vitamin D, selenium, etc. can harm in excess). orpha.net+1

8) Eat “brain-support” foods (fish/omega-3 sources when safe) and avoid unsafe raw foods if immunity is weak. PubMed+2Frontiers+2

9) If reflux exists, smaller meals help and avoid late-night heavy meals. FDA Access Data+2PMC+2

10) Avoid alcohol completely (especially with liver disease) and avoid unreviewed herbal products that may hurt the liver. Wiley Online Library+2PMC+2

FAQs

1) Is CCDC115-CDG curable? There is no proven cure yet; treatment is supportive and symptom-based while research continues. PMC+2PMC+2

2) Why is the liver often affected? CCDC115 problems disturb Golgi function and glycosylation, which can strongly impact liver processing and protein handling. PMC+2Wiley Online Library+2

3) Can it look like Wilson disease or other liver diseases? Yes, reports show it can mimic other liver/metabolic disorders, delaying diagnosis. PubMed+2Genetic Diseases Info Center+2

4) What test suggests a CDG problem? Many CDGs are detected by abnormal glycosylation screening in blood proteins, then confirmed by genetic testing. PMC+2PMC+2

5) Is it inherited? Yes, it is usually autosomal recessive (both parents carry one changed gene copy). orpha.net+2Genetic Diseases Info Center+2

6) Can siblings be tested? Often yes—families can discuss carrier testing or testing for symptoms with genetics providers. orpha.net+2NCBI+2

7) Do all patients have seizures? Not all, but seizures have been reported; neurologists decide monitoring and treatment. Genetic Diseases Info Center+2PMC+2

8) Why are clotting problems possible? Liver dysfunction and abnormal glycosylation can affect clotting proteins, raising bleeding risk. NCBI+2Genetic Diseases Info Center+2

9) Are supplements always needed? No. Supplements are best used when blood tests or diet show a real need. orpha.net+2PubMed+2

10) Can immune weakness happen? Some glycosylation disorders can affect immune function, but patterns differ; evaluation is individualized. Frontiers+2PMC+2

11) What does “multidisciplinary” care change? It helps detect problems earlier and improves daily functioning support (nutrition, therapy, schooling). PMC+2PMC+2

12) Is liver transplant ever needed? In progressive liver failure, transplant may be considered, but it does not correct the gene in other organs. Genetic Diseases Info Center+2Wiley Online Library+2

13) Why are rifaximin and lactulose mentioned? They are standard options for hepatic encephalopathy prevention/treatment in chronic liver disease settings. AASLD+2AASLD+2

14) Are stem cell “cures” available? Not as a standard cure for CCDC115-CDG; stem cell approaches are complex and usually limited to special situations or research. PMC+2ScienceDirect+2

15) What specialists are most important? Genetics/metabolic, hepatology (liver), neurology, dietitian, and therapy teams are commonly central to care. PMC+2PMC+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 15, 2025.